Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOESTRIN 24 FE vs ESTARYLLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration. Alters endometrial development, decreasing implantation likelihood.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
FDA-approved: Prevention of pregnancy.,Off-label: Treatment of acne vulgaris, regulation of menstrual disorders, dysmenorrhea.
FDA-approved: Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.,Off-label: Acne vulgaris (for norgestimate-containing pills), management of menstrual disorders (e.g., dysmenorrhea, abnormal uterine bleeding), hormone therapy for transgender women (non-standardized).,Note: Off-label uses are not FDA-approved for this specific formulation.
One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 24 days, followed by a low-dose iron-containing tablet (75 mg ferrous fumarate) for 4 days.
One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.
Norethindrone: 5-12 hours; Ethinyl estradiol: 13-27 hours. The terminal half-life supports once-daily dosing; steady state is achieved within 5-7 days.
Terminal elimination half-life of ethinyl estradiol is approximately 13-16 hours; clinical context: steady-state achieved within 5-7 days
Ethinyl estradiol undergoes CYP3A4-mediated hydroxylation and glucuronidation; norethindrone is metabolized via reduction, glucuronidation, and sulfation, primarily by CYP3A4 and CYP2E1.
Ethinyl estradiol is primarily metabolized by CYP3A4, with conjugation to glucuronides and sulfates. Norgestimate is rapidly metabolized to its active metabolite, norelgestromin, and further to levonorgestrel; involvement of CYP2C19 and CYP3A4 in norgestimate metabolism is noted.
Ethinyl estradiol and norethindrone are primarily excreted in urine (about 50-60%) and feces (about 30-40%) as glucuronide and sulfate conjugates after hepatic metabolism.
Renal: ~55% as metabolites, ~27% unchanged; Fecal: ~45% as metabolites
Norethindrone: ~97% bound, primarily to sex hormone-binding globulin (SHBG) and albumin. Ethinyl estradiol: ~97% bound, primarily to albumin and SHBG.
Ethinyl estradiol: 97-98% bound to albumin, with minor binding to sex hormone-binding globulin
Norethindrone: approximately 3.6 L/kg; Ethinyl estradiol: approximately 2.7 L/kg. Large Vd indicates extensive tissue distribution (reproductive organs, liver, fat).
Ethinyl estradiol: approximately 2.8 L/kg; indicates extensive tissue distribution
Norethindrone: approximately 64% (oral) due to first-pass metabolism. Ethinyl estradiol: approximately 55% (oral) due to first-pass metabolism and intestinal conjugation.
Oral: approximately 55% due to first-pass metabolism; consistent in healthy females
No dosage adjustment required for mild to moderate renal impairment. Not recommended for use in patients with severe renal impairment or end-stage renal disease due to lack of data.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in severe renal impairment or end-stage renal disease due to lack of data.
Contraindicated in patients with hepatic disease, including acute hepatitis, hepatic adenomas, or cirrhosis. No dose adjustment recommendations; avoid use.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; dose adjustment not specifically defined, but alternative contraception recommended.
Approved for use in postmenarchal females. Dosage same as adults: one active tablet daily for 24 days followed by iron-containing tablets for 4 days. Not indicated for premenarchal females.
Approved for use in postmenarchal adolescents: same dosing as adults (one tablet daily for 21 days, then 7 days placebo). No weight-based dosing required.
Not indicated for use in postmenopausal women. No specific dosing recommendations; therapy should be discontinued if menopause occurs.
Not indicated in postmenopausal women. No specific geriatric dosing; contraindicated in women over 60 years due to increased thromboembolic risk.
Cigarette smoking increases risk of serious cardiovascular events (thrombosis, myocardial infarction, stroke) from combination oral contraceptives, especially in women over 35 who smoke >15 cigarettes/day.
Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptives. This risk increases with age (especially in women over 35 years of age) and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders, hypertension, gallbladder disease, hepatic neoplasia, retinal thrombosis, carbohydrate/lipid effects, headache, menstrual irregularities, depression, hereditary angioedema.
Thrombotic disorders: Increased risk of venous thromboembolism (VTE) and arterial thromboembolism (e.g., MI, stroke). Discontinue if thrombotic event occurs.,Cardiovascular disease: Avoid in women with uncontrolled hypertension, diabetes with vascular involvement, or history of thromboembolic disease.,Cigarette smoking: Strongly advise cessation, especially in women over 35.,Liver disease: Discontinue if jaundice or cholestasis develops; contraindicated in acute viral hepatitis or severe cirrhosis.,Hormone-dependent malignancies: Increased risk of breast cancer (current use) and cervical cancer; avoid if known or suspected breast cancer.,Gallbladder disease: Increased risk of gallstones.,Carbohydrate and lipid metabolism: Monitor glucose and lipids in predisposed patients; may impair glucose tolerance and increase triglycerides.,Headache: Evaluate if new-onset or worsening migraine, especially with focal neurological symptoms.,Uterine bleeding: Rule out pregnancy if amenorrhea occurs; irregular bleeding may require evaluation.,Depression: Monitor for mood changes; discontinue if severe depression recurs.,Angioedema: Risk in women with hereditary angioedema.
Thrombophlebitis/thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected pregnancy, undiagnosed abnormal genital bleeding, known/suspected breast cancer, hepatic tumors (benign/malignant), hypersensitivity to any component, smoking >15 cigarettes/day in women >35 years.
Known or suspected pregnancy,Current or past venous thrombosis (e.g., deep vein thrombosis, pulmonary embolism),Current or past arterial thrombosis (e.g., myocardial infarction, stroke) or prodromal conditions (e.g., angina, transient ischemic attack),Known thrombophilic disorders (e.g., Factor V Leiden, prothrombin mutation, antithrombin deficiency),History of cerebrovascular or coronary artery disease,Uncontrolled hypertension (sustained >160/100 mm Hg),Diabetes mellitus with nephropathy, retinopathy, neuropathy, or other vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura) in women over 35,Current or past breast cancer, or other estrogen- or progestin-sensitive cancer,Active liver disease (e.g., acute viral hepatitis, severe cirrhosis) or benign/malignant liver tumors,Undiagnosed abnormal uterine bleeding,Hypersensitivity to any component of Estarylla,Use of highly active antiretroviral therapy (HAART) containing ritonavir or direct-acting antivirals for hepatitis C (e.g., ombitasvir/paritaprevir/ritonavir) due to potential for hepatotoxicity
No specific food interactions. Grapefruit juice may increase ethinyl estradiol levels; avoid excessive consumption. Alcohol does not affect efficacy but may worsen side effects like nausea or dizziness. The ferrous fumarate in placebo pills may be absorbed better with vitamin C (e.g., orange juice).
There are no known significant food interactions. Grapefruit juice may increase estrogen levels but clinical significance is unclear; consider moderate intake.
First trimester: Postmarketing studies have not shown an increased risk of birth defects with oral contraceptives. Second and third trimesters: Contraindicated due to potential adverse effects on fetal development including possible estrogenic effects on fetal genitalia. Discontinue if pregnancy occurs.
Estarylla (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive. Use during pregnancy is contraindicated. First trimester: No strong evidence of major malformations from inadvertent exposure, but increased risk of cardiovascular and limb defects in some studies. Second and third trimesters: Associated with fetal harm, including cardiovascular effects (e.g., congenital heart defects) and possible estrogenic effects, though data are limited. Postnatal effects: Potential long-term developmental effects unknown. Overall risk is low but not zero; avoid use in pregnancy.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio not established. Use may reduce milk production and composition. Not recommended during breastfeeding; consider alternative contraception.
Estarylla is excreted in breast milk in small amounts (ethinyl estradiol: M/P ratio ~0.2; levonorgestrel: M/P ratio ~0.3-0.4). Combined hormonal contraceptives may reduce milk production and affect milk composition, especially in early postpartum. Use is generally not recommended until breastfeeding is well-established (at least 6 weeks postpartum). For later use, progestin-only methods are preferred. Monitor infant for jaundice and growth.
No dosing adjustments are applicable as Loestrin 24 Fe is contraindicated during pregnancy. Discontinue immediately upon pregnancy confirmation.
Estarylla is contraindicated in pregnancy. No dosing adjustments are recommended because it should not be used. Pregnancy alters pharmacokinetics of oral contraceptives (e.g., increased volume of distribution, altered hepatic metabolism), but no dose changes are indicated due to contraindication. If inadvertently taken, discontinue immediately.
Loestrin 24 Fe contains norethindrone acetate and ethinyl estradiol with 24 active tablets and 4 ferrous fumarate placebo tablets. It is approved for contraception and acne vulgaris in women ≥16 years. The shortened hormone-free interval (4 vs 7 days) may reduce breakthrough bleeding and improve ovarian suppression. Counsel patients that the iron tablets are not active hormone and serve only to maintain routine. If a dose is missed, the patient should take the missed pill as soon as remembered and continue the remaining pills, possibly requiring backup contraception. Breakthrough bleeding is common in the first few cycles; rule out pregnancy if persistent.
Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It is indicated for prevention of pregnancy. Monitor for thromboembolic events, especially in smokers over 35. Counsel on missed dose management: take as soon as remembered, use backup contraception if more than 24 hours late. May reduce menstrual cramps and acne. Not recommended in patients with history of estrogen-dependent neoplasia, liver disease, or uncontrolled hypertension.
Take one pill daily at the same time, preferably after a meal to reduce nausea.,The 4 brown pills contain iron; they are not hormonal and are taken during the placebo week.,Use backup contraception (condoms) for the first 7 days if starting for the first time or after a break.,Missing pills increases risk of pregnancy; follow package instructions for missed doses.,Do not smoke while taking this medication, especially if over 35 years old, due to increased risk of blood clots.,Report severe abdominal pain, chest pain, shortness of breath, headache, visual changes, or leg pain/swelling.,Regular gynecological exams and blood pressure monitoring are recommended.,Store at room temperature away from moisture and heat.
Take one pill daily at the same time each day.,If you miss a pill, take it as soon as remembered; use backup contraception if more than 24 hours late.,Do not smoke while taking this medication, especially if over 35.,Report any signs of blood clots: leg pain, chest pain, shortness of breath, or sudden vision changes.,This medication does not protect against HIV or other STDs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOESTRIN 24 FE vs ESTARYLLA, answered by our medical review team.
LOESTRIN 24 FE is a Combined Oral Contraceptive that works by Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration. Alters endometrial development, decreasing implantation likelihood.. ESTARYLLA is a Combined Oral Contraceptive that works by Estarylla is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It suppresses gonadotropin release (FSH and LH) via estrogen and progestin, inhibiting ovulation. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOESTRIN 24 FE and ESTARYLLA depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOESTRIN 24 FE is: One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 24 days, followed by a low-dose iron-containing tablet (75 mg ferrous fumarate) for 4 days.. The standard adult dose of ESTARYLLA is: One tablet (0.02 mg ethinyl estradiol and 0.15 mg desogestrel) orally once daily for 21 days, followed by 7 days of placebo. Hormone-free interval of 7 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOESTRIN 24 FE and ESTARYLLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOESTRIN 24 FE is classified as Category C. First trimester: Postmarketing studies have not shown an increased risk of birth defects with oral contraceptives. Second and third trimesters: Contraindicated due to potential adv. ESTARYLLA is classified as Category C. Estarylla (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive. Use during pregnancy is contraindicated. First trimester: No strong evidence of major malformations f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.